Since the 2016 WHO classification of the central nervous system tumors [36] and advances in immunohistochemistry, glioblastomas are now defined by their Isocitrate dehydrogenase (IDH) status dividing this entity into glioblastoma IDH-mutant or IDH-wild type. This evidence concerns the gene IDH1 and central nervous system cancer.